Clinical Trials List
2023-12-31 - 2026-03-18
Phase III
Recruiting8
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
xxxxxx
-
Sponsor
xxxxxx
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wei-Pang Chung 無
- Chun-Hui Lee 無
- Jui-Hung Tsai 無
- 楊舜如 無
- Shang-Hung Chen 無
- Zhu-Jun Loh 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 劉惠文醫師 Division of Hematology & Oncology
- 蘇智銘醫師 Division of General Surgery
- 譚家偉醫師 Division of General Surgery
- 莊博雅醫師 無
- Yao-Yu Hsieh 無
- Wei-Hong Cheng 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林欣辰醫師 無
- 楊陽生 無
- ZHENG-WEI ZHOU 無
- Huey-En Tzeng Division of Hematology & Oncology
- 王國鐘 Division of General Surgery
- 陳維信 無
- I-Chen Tsai 無
- 林慈恩醫師 Division of General Surgery
- 劉佳樺醫師 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
85 participants
-
Global
5500 participants
